Detalles de la búsqueda
1.
Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence.
Int J Cancer
; 2024 Feb 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38380807
2.
Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal Study.
Clin Gastroenterol Hepatol
; 22(3): 572-580.e5, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37734582
3.
Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.
Liver Int
; 44(6): 1343-1350, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38436529
4.
Kinetics of the hepatitis B core-related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide.
Hepatol Res
; 2024 Apr 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38685853
5.
Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
J Gastroenterol Hepatol
; 39(5): 949-954, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38291715
6.
Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study.
J Gastroenterol Hepatol
; 2024 Mar 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38480009
7.
Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Oncologist
; 28(7): e526-e533, 2023 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37023703
8.
Clinical outcomes of antithrombin III-based therapy for patients with portal vein thrombosis: A retrospective, multicenter study.
Hepatol Res
; 53(1): 51-60, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36136893
9.
Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
Hepatology
; 74(2): 656-666, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33706421
10.
The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma.
BMC Cancer
; 22(1): 912, 2022 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35999529
11.
A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma.
BMC Cancer
; 22(1): 517, 2022 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35525913
12.
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis.
Hepatol Res
; 52(3): 269-280, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34761470
13.
Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.
Hepatol Res
; 52(3): 235-246, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34861090
14.
Misunderstanding of hepatitis C virus (HCV) infection status by non-specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy.
J Infect Chemother
; 28(9): 1231-1234, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35534339
15.
NAFLD exacerbates cholangitis and promotes cholangiocellular carcinoma in mice.
Cancer Sci
; 112(4): 1471-1480, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33506599
16.
Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir.
Am J Gastroenterol
; 116(6): 1264-1273, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34074829
17.
Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study.
BMC Cancer
; 21(1): 1169, 2021 Oct 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34717577
18.
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis.
Hepatol Res
; 51(2): 201-215, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33270323
19.
Liver stiffness does not affect ultrasound-guided attenuation coefficient measurement in the evaluation of hepatic steatosis.
Hepatol Res
; 50(2): 190-198, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31661724
20.
Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan.
J Gastroenterol Hepatol
; 35(8): 1420-1425, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31950525